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Gastrointestinal symptoms, and elevated liver enzymes, are common after HSCT, often due 
to drug toxicity, graft-versus-host disease (GVHD) or infections. It is essential to 
distinguish between GVHD and infection, since both conditions may progress to lethal 
disease, but require opposite strategies for the immunosuppressive treatment. Several of the 
viral gastrointestinal infections are easily transmitted and can cause outbreaks in health care 
facilities.  
In this thesis I studied viral gastrointestinal infections in HSCT patients, with focus on 
human adenovirus (HAdV), norovirus and hepatitis E virus (HEV), addressing transmission 
within health care, clinical importance, risk factors for severe/prolonged disease and the 
importance of secretor-status.  
In paper I we analyzed an outbreak of HAdV at the Center for Allogeneic Hematopoietic 
Stem Cell transplantation (CAST), Karolinska University Hospital. We identified nine 
patients with HAdV A31. Hygiene measures were implemented, but the outbreak continued 
for a prolonged time. High strain on the staff during the early part of the outbreak, possible 
contamination of the facilities of the ward, and unidentified cases with sparse symptoms, 
may have contributed to the prolonged outbreak. The clinical consequences were 
significant, although no patient developed severe HAdV disease.  
Paper II was a retrospective study of the clinical importance, and risk factors for long-term 
symptoms, in 63 HSCT patients with norovirus infection. In paper III, we analyzed if 
secretor-status influenced the clinical course of norovirus infection in 89 HSCT patients 
with norovirus infection, of whom 63 also had been included in paper II.  
we found chronic symptoms of norovirus (>30 days) in 18/89 (20%) of the patients. Severe 
combined immunodeficiency (SCID) diagnosis was associated with chronic norovirus 
symptoms in both paper II and III, which may be due to the delayed immune reconstitution 
in many of these patients. The number of secretor-negative patients was low compared to 
the general population, indicating that secretor-negative genotype may protect against 
norovirus even when the patient is severely immunocompromised.  
Paper IV was a retrospective study of the frequency and clinical importance of HEV 
infection in a cohort of 236 HSCT recipients. HEV RNA was detected in 8/236 (3.4%) 
patients 6 months after HSCT. We found that elevated alanine aminotransferase (ALT) at 
six months after HSCT was associated with HEV infection. Spontaneous clearance was 
common, but one patient died of multiorgan failure where HEV infection may have 
contributed. 
In conclusion, we found that an outbreak of HAdV can be difficult to control and may have 
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serious consequences. Norovirus causes chronic symptoms (> 30 days) in 20% of HSCT 
patients, and SCID as indication for HSCT is associated with a chronic course of norovirus 
infection. We found that problems discriminating symptoms of HAdV, or norovirus, from 
symptoms of gastrointestinal GVHD, are a significant clinical challenge. HEV infection is 
an infrequent, but potentially severe, differential diagnosis in patients with elevated ALT 
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1.1 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 
(HSCT) 
Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment where an abnormal 
hematopoiesis is replaced by hematopoetic cells from a healthy individual. As survival after 
HSCT has improved over the years, the indications for HSCT have broadened.  In adults the 
majority of HSCTs are performed for treatment of hematological malignancies (mainly acute 
leukemia, but also chronic leukemia, myelodysplastic syndrome, lymphomas and multiple 
myeloma), whereas in children, non-malignant diagnoses dominate. HSCT can eliminate or 
control residual malignant cells, since the new immune system will attack these cells. This is 
termed graft-versus-leukemia (GVL) effect and is considered to be the main requirement for 
long-term disease control in patients with hematological malignancy1,2. It has been shown 
that graft-versus-host disease (GVHD) is associated with a GVL effect2. In addition to this 
effect, HSCT enables a more intensive chemotherapy, and total body irradiation, since bone 
marrow toxicity is a main limiting factor.  
HSCT is also used as replacement therapy for non-malignant disorders. These are congenital 
or acquired deficiencies of marrow function, the immune system, or enzyme deficiencies, 
including a wide range of diseases, such as thalassemia, aplastic anemia, inborn errors of 
metabolism, and severe combined immunodeficiency (SCID). In patients with non-malignant 
disorders, GVHD should be avoided since there is no beneficial anti-tumor effect and GVHD 
prophylaxis should therefore be optimized.  
1.1.1 The donor and source of stem cells 
The question of which donor to choose has become more complicated in recent years with the 
introduction of haploidentical donors. Traditionally, the donor of stem cells should be as well 
matched for human leukocyte antigen (HLA) as possible, to avoid severe complications of 
HSCT. However, several studies have shown that comparable or even better results can be 
obtained by using a haploidentical donor as with an unrelated donor with “moderate degree” 
of mismatch (1/8)3. Other factors that can be considered for the choice of a suitable donor, are 
cytomegalovirus (CMV) match, sex, age of the donor and blood group.  
The preferred choice is still an HLA-matched sibling, which is available in approximately 
25% of the patients. The second choice is usually a well-matched (8/8) unrelated donor 
(URD) obtained from the worldwide registries of stem cells donors. Haplo-identical family 
donors (usually child or parent, with half of the HLA-antigens identical) have been 
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increasingly used lately with the improving outcome. For children, umbilical cord blood (CB) 
donor is an alternative, but are rarely used for adults, due to the low cell dose. The source of 
hematopoietic stem cells is today mostly peripheral blood, after mobilization of stem cells 
with colony stimulating factor, but hematopoietic stem cells can also be harvested from bone 
marrow, or from umbilical cord blood. The preferred stem cell source may however depend 
on the diagnosis and can vary between different HSCT centers. 
1.1.2 Conditioning regimen 
Prior to infusion of harvested hematopoietic stem cells, the patient receives a cytotoxic 
conditioning treatment. The purpose of the conditioning treatment is to minimize the number 
of malignant cells in the host, if the reason for HSCT is malignant disease, and to prevent 
graft rejection. The conditioning therapy has historically been myeloablative (MAC), where 
the hematopoiesis may not recover without infusion of hematopoietic stem cells. Reduced 
intensity conditioning (RIC) is associated with less toxicity and shorter neutropenia and has 
enabled HSCT in older patients, and in patients with co-morbidities. Since it has been 
acknowledged that cure of malignant disease after HSCT, to a large extent depends on the 
GVL effect, RIC regimens have become more commonly used in recent years. There are 
many different conditioning protocols and they are now divided into MAC, RIC and non-
myeloablative (non-MAC) regimens, with non-MAC being the least intense. The choice of 
conditioning depends on the indication for HSCT, the age of the patient and occurrence of co-
morbidities. 
1.1.3 GVHD 
GVHD appears when the donor immune cells react to the recipient cells and is one of the 
most severe complications after HSCT. Acute GVHD usually occurs during the first 3 
months after HSCT, and chronic GVHD later than 3months. However, the timing has become 
more diverse and is overlapping with the introduction of RIC, donor lymphocyte infusion 
(DLI) and late tapering of immunosuppressive drugs4,5.  
Acute GVHD most commonly affects the skin, the gastrointestinal tract and the liver. 
Pathophysiology involves three steps. (1) Tissue damage caused by the conditioning, the 
underlying disease and/or its treatment, causes release of inflammatory cytokines and 
chemokines, which will activate recipient APCs. Disrupted barriers with translocation of 
microbial products, such as lipopolysaccharides, will further enhance this activation. (2) 
Recipient APCs interact with donor T-cells, causing activation, proliferation and migration of 
allo-reactive T-cells, and also of NK-cells. (3) Tissue damage by cytotoxic T-cells and NK-
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cells, with release of proinflammatory mediators, further contributing to the cytokine storm.  
The incidence of acute GVHD varies between 30-70%, depending on the degree of HLA 
matching, type of donor, conditioning regimen and age of the patient. A commonly used 
prophylaxis against GVHD is cyclosporine and short term methotrexate, with addition of in 
vivo depletion of T-cells in patients with an increased risk of GVHD, such as those with an 
unrelated donor. 
Acute GVHD is graded I-IV according to the severity of organ involvement6, with GVHD 
grade III-IV carrying a high mortality7. The diagnosis is mostly clinical, although 
histopathological evaluation can be essential to differ from other diseases, such as CMV 
colitis8. Standard first line treatment for acute GVHD is corticosteroids and continued 
prophylaxis with cyclosporine (or another calcineurin inhibitor). The response rate on 
corticosteroid treatment decreases with the grade of GVHD but is generally approximately 
40-50%. Steroid refractory acute GVHD is a severe complication with significant mortality. 
Several different therapies have been used over the years with varying efficacy but none of 
these have been shown to be clearly superior. Ruxolitinib has recently been shown in 
randomized controlled trials to be more effective than “best available therapy” and is now 
seen as the primary choice for treatment of steroid refractory acute GVHD9. Other promising 
options are mesenchymal stem cells, especially in children, and photopheresis. Several other 
agents have been tried for second-line therapy but data for these therapies are insufficient for 
a general recommendation10 
Chronic GVHD affects 25-65% of long-term survivors and is one of the leading causes of 
late morbidity and mortality after HSCT. A major risk factor for chronic GVHD is preceding 
acute GVHD. The main target is connective tissue in various organs, resulting in dermatitis, 
keratoconjunctivitis, oral mucositis, enteritis or liver affection. A particularly difficult form of 
chronic GHVD is obliterative bronchiolitis that can cause respiratory failure. The diagnosis 
depends primarily on clinical signs (with exclusion of other differential diagnoses) and is 
graded mild, moderate or severe4. The first line treatment for chronic GVHD is 
corticosteroids, usually in combination with a calcineurin inhibitor to reduce the dose and 
duration of corticosteroids. Approximately 20% of adults and 50% of children respond to 
corticosteroids. There is no consensus concerning second-line therapy for chronic GVHD, but 
a large variety of treatments are used, including extracorporeal photopheresis, mycophenolate 
mofetil, rituximab, calcineurin inhibitors, mammalian target of rapamycin (mTOR) 
inhibitors, tyrosine kinase inhibitors, and ruxolitinib10  
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Both acute and chronic GVHD impair the immune reconstitution, due to GVHD itself and the 
immunosuppressive treatment11,12. 
 
1.1.4 Immune reconstitution 
Reconstitution of the immune system is affected by various factors, such as age, conditioning 
regimen, type of donor, stem cell source, graft manipulation (T-cell depletion), the 
development of GHVD or recurrence of the underlying disease, illustrated in Figure 1. The 
cells of the innate immune system, including granulocytes, monocytes and NK cells, 
normally recover in number and function during the first 1-2 months after HSCT, with 
neutrophils being the first leucocyte to appear in peripheral blood. However, important 
functions of innate immune cells, such as chemotaxis and phagocytosis, can remain impaired 
over a longer period, especially if the patient develops GHVD. Macrophages are more 
resistant to chemotherapy and early on tissue macrophages of host origin remain, but 
gradually they are replaced by donor macrophages.  
The reconstitution of the adaptive immune system takes longer. The reconstitution of T-cells 
(CD3+ cells) occurs by two main pathways. Initially there is an early thymus-independent 
peripheral expansion of mature donor T-cells from the graft, providing a limited repertoire of 
T-cells during the first year after HSCT.  Secondly, there is generation of naïve donor T-cells, 
that undergo thymus-dependent maturation. This process takes six months up to two years. 
The thymus function, and thereby the thymus-dependent maturation of T-cells, is dependent 
on several factors, especially older age and the occurrence of GVHD13. The CD4+ helper T-
cells reconstitute later than CD8+ cytotoxic T-cells, resulting in an inversed CD4/CD8 ratio 
seen early after HSCT.  
B-cells usually reach normal levels after 1-2 years, but recovery of memory B-cells takes 
longer, leading to a prolonged defect humoral immune response, especially in patients with 
GVHD. The impaired function of CD4+ helper T-cells further hampers an efficient antibody 





Figure 1. Illustration of the recovery of the number of different immune cells after HSCT, and factors that can 
influence the immune reconstitution.  
Image from Stern L, McGuire H, Avdic S, Rizzetto S, Fazekas de St Groth B, Luciani F, Slobedman B and 
Blyth E (2018) Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell 
Transplantation. Frontiers in Immunology14 
 
1.1.5 Infections after HSCT 
Infections are a major cause of morbidity and mortality following HSCT. The spectrum and 
risk for infections varies depending on the time that has passed since HSCT, and if 
complications affecting the immune recovery, especially GVHD or relapse, have evolved.  
The process of immune reconstitution, and the corresponding risk for infections, has 
traditionally been divided into three phases: the pre-engraftment phase (0-30 days after 
HSCT), the early post-engraftment phase (30-100) days after HSCT), and the late post-
engraftment phase (>100 days after HSCT). However, in recent years, the infectious 
panorama of the early post-engraftment period can be found for longer, until approximately 
180 days post HSCT, depending on the type of conditioning, type of donor, T-cell depletion, 
and stem cell source, all possibly impacting immune reconstitution. GVHD is the most 
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important risk factor for infections in the late post-engraftment phase, and if GVHD does not 
occur, the risk is generally lower for most infections after day 100 (180).  
 
The pre-engraftment phase (day 0-30) 
During the first 2-4 weeks after HSCT, bacterial infections are dominating, usually as blood 
stream infections, due to neutropenia, disruption of the mucosal barriers, and indwelling 
catheters. The dominating etiologies are enteric gram-negative rods and gram-positive cocci, 
translocated from the gastrointestinal tract, and coagulase-negative staphylococci, originating 
from the skin and central venous catheters15,16. Bacteremia in a neutropenic patient carries a 
high mortality, if not treated adequately, and empirical broad-spectrum antibiotic treatment 
should always be administered to neutropenic patients with fever17,18. Bacteremia with gram-
negative rods are associated with the highest mortality, and many centers provide the patients 
with quinolone prophylaxis during the neutropenia. Quinolone prophylaxis reduces the 
number of episodes with fever and bacteremia, respectively, but there is no confirmed effect 
on mortality19. During pre-engraftment there is also a risk for candida mucositis and invasive 
candida infection unless prophylaxis is given. The risk for invasive mold infections is 
generally moderate but increases especially in patients with previous invasive mold infection, 
cord blood transplantation, or patients with active leukemia at the time of HSCT20. 
Prophylaxis with antifungal agents is generally recommended: fluconazole if there is a low 
incidence of mold infections at the center, or a mold-active agent such as posaconazole if the 
incidence is high, or in patients with an increased risk21.  
Herpes simplex 1 and 2 reactivations are common during this phase motivating prophylaxis 
with acyclovir. On the contrary, the risk of reactivating other latent or persistent viruses is 
low during this phase, although children with pre-transplant shedding of human adenovirus 
(HAdV) in stool, can develop invasive HAdV infection early after HSCT22-24. Community 
acquired respiratory viral infections, especially influenza, respiratory syncytial virus (RSV), 
and parainfluenza, can cause severe pneumonia with high mortality during the pre-
engraftment phase. The new coronavirus, severe acute respiratory syndrome coronavirus 2 
(SARS CoV2), may cause lethal pneumonia in 20% of patients who become infected within 
the first year after HSCT25. 
If the mentioned respiratory viral infections (including HAdV in respiratory secretions), or 





The early post-engraftment phase (day 30-100 (180)) 
Following recovery of neutrophils, the risk of infections with enteric bacteria is greatly 
diminished. The risk of bacteremia with coagulase-negative staphylococci is also reduced, but 
the risk remains as long as the patient has a central venous catheter. During the early post-
engraftment phase the infections mainly reflect the profound defect of cellular immunity in 
the patients. Reactivations of cytomegalovirus (CMV) are common, and since there is a high 
risk of disease, monitoring and pre-emptive therapy with ganciclovir have been standard22,27. 
Recently, prophylaxis with a new antiviral drug, letermovir, was shown to reduce the number 
of clinically significant CMV infections and reduce all-cause mortality by week 24 after 
HSCT28. Prophylaxis with letermovir has therefore been implemented at many centers.  
Reactivation of Epstein-Barr virus (EBV) with the development of post-transplant 
lymphoproliferative disease is a serious complication with high mortality23. High risk patients 
should be monitored for EBV in blood 29. HAdV can be reactivated or acquired with the risk 
of lethal disseminated disease, which is described in more detail in the HAdV section. 
Children should be monitored for HAdV in blood, and some centers also monitor the level of 
HAdV in stool30. There is a substantial risk for reactivation of varicella zoster virus and 
seropositive patients should receive prophylaxis with acyclovir/valaciclovir during the first 
year post HSCT31. Community acquired respiratory virus infections, especially influenza and 
respiratory syncytial virus, continue to be important pathogens during this period. 
The risk for invasive mold infection is high in patients with acute GVHD III-IV, acute 
GVHD > II in patients > 40 years or with an alternative donor, acute GVHD followed by 
chronic GVHD, or GVHD unresponsive to steroids21,32,33. Pneumocystis jirovecii pneumonia 
(PJP) is common without prophylaxis, which is routinely given during this period34. Other 
fungal infections are uncommon in the absence of GVHD.  
 
The late post-engraftment phase (> day 100 (180)) 
The risk of infections during this phase is highly associated with the occurrence of chronic 
GVHD.  In patients without GVHD, there is a moderate risk for infections with encapsulated 
bacteria (Streptococcus pneumoniae and Haemophilus influenzae). Vaccination against these 
bacteria with conjugated vaccines is recommended from 3 months after HSCT, and during 
season patients should be vaccinated against influenza35,36. The risk for PJP continues, and 
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prophylaxis should be prescribed at least until the GVHD prophylaxis has been terminated. 
Reactivation of VZV can also occur, motivating continued prophylaxis for at least a year.  
In patients with GVHD, the risk of infections is related to the severity of GVHD, and the 
treatment required, including the dose and duration of corticosteroids. The infections seen are 
related to the delayed reconstitution of both the cellular and humoral immune system in 
patients with GVHD. Hence, there can be reactivations of CMV, which may require 
continued monitoring27,37. There is an increased risk for infections with Streptococcus 
pneumoniae and Haemophilus influenzae, and antibiotic prophylaxis can be considered in 
patients with severe chronic GVHD. Influenza continues to be important and yearly 
vaccination is recommended as long as the patient is assessed to be immunocompromised. 
Prophylaxis for PJP needs to be continued, and patients with severe GVHD are at risk of 
invasive mold infections.  
Hepatitis B can cause severe complications including fibrosing cholestatic hepatitis due to 
reactivation of the infection after HSCT38. All patients with chronic hepatitis B infection 
(who are not on antivirals) should receive antiviral treatment, life-long. Patients with previous 
hepatitis B also have a high risk of reactivating the infection and antiviral prophylaxis is 
recommended from the time of HSCT and until at least a year after the immunosuppression 
has been terminated38. HSCT patients with previous or chronic hepatitis B should be 
monitored for reactivation. For patients without hepatitis A or hepatitis B antibodies, 
vaccination can be considered, before and after the HSCT. Patients with chronic hepatitis C 
are at risk for accelerated development of cirrhosis after HSCT and should receive treatment 
as soon as regarded possible38. In some countries, although not in Sweden, screening for 
hepatitis E has been implemented, since hepatitis E has emerged as a cause of liver injury 
following HSCT39. 
 
1.2 HUMAN ADENOVIRUS (HADV) 
Infections with HAdV are common, especially in young children. There are currently more 
than 100 HAdV types, which are grouped into seven species (A-G)40. HAdVs are genetically 
heterogenous viruses that can infect several different cell types and organs. The tissue tropism 
varies between HAdV types, rendering a broad variety of symptoms, including upper or 
lower respiratory tract infection, gastroenteritis and conjunctivitis41. In immunocompetent 
individuals HAdV infections are usually mild and self-limiting, although severe 
manifestations with lethal pneumonia, encephalitis or myocarditis also may occur42,43.  
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The circulating types of HAdV varies over time and between geographical areas. However, 
the knowledge of circulating HAdV types, both in the society and in health care facilities, is 
limited, since HAdV typing is uncommon in routine laboratory testing. The most common 
HAdV types reported in the general population are types C1, C2, C5, B3, B7, B14, B21, E4, 
and F41 44,45. The types of HAdV reported in HSCT patients are similar to those found in the 
general population, with C1, C2, C5, B3 and B7 dominating, apart from HAdV A31 having 
been found more frequently in HSCT patients41,46-49.  
 
1.2.1 HAdV persistence and reactivation 
Healthy children can excrete virus in stool for months or even years after the primary 
infection50,51, and HAdV has been shown to persist in different cell types and tissues52. 
Garnett et al reported of HAdV DNA in lymphocytes in tonsils and adenoids. The prevalence 
was highest in young children and declined with increasing age. Infectious HAdV was rarely 
found, but HAdV DNA replication and production of infectious virus appeared at stimulation 
of the lymphocytes, indicating a latent form of HAdV52,53. Since clearance of HAdV DNA 
seems to occur with increasing age, unlike what is seen in other viruses capable of true 
latency (herpes viruses and human immunodeficiency virus)54, we here use the term 
“persistence” for HAdV. 
 Kosulin et al. studied gastrointestinal biopsies from immunocompetent and HSCT children. 
Using in situ hybridization, HAdV DNA was identified in gastrointestinal lymphocytes from 
the immunocompetent children, whereas in HSCT children HAdV DNA was located mainly 
in the gastrointestinal epithelial cells. This could indicate that lymphocytes are the primary 
site of HAdV persistence, but when reactivated, leaking viruses from lymphocytes replicate 
more readily in epithelial cells55.  HAdV DNA has also been detected in lymphocytes 
infiltrating tumors, but it has not been shown whether HAdV has a potential oncogenic role in 
humans56. Persistent HAdV may reactivate in severely immunocompromised patients, 
especially in the HSCT setting41. Detection of HAdV antibodies before HSCT has predicted 
reactivation of the same HAdV type after HSCT57, and a HAdV strain identified prior to 
HSCT was with few exceptions identical to the HAdV strain found after HSCT57,58. Although 
HAdV may persist in several tissues, many studies indicate that the gastrointestinal tract is 




1.2.2 HAdV, transmission 
HAdV is transmitted by droplets, direct contact, fecal-orally, or indirectly by contaminated 
objects41. HAdV particles are highly resistant physically. HAdV has been shown to remain 
infectious on dry surfaces for up to four weeks62,63 and HAdV DNA can remain detectable on 
surfaces for three months64. Since HAdV are non-enveloped viruses, they are resistant to 
many hand disinfectants, although the sensitivity can vary between HAdV types65. For 
inactivation of HAdV, a solution with 85% ethanol for at least 2 minutes is effective65. 
Surfaces and fomites can also be disinfected with an oxidative agent or sodium hypochlorite 
for 10 minutes66,67.  
 
HAdV can be easily transmitted and cause outbreaks in closed or crowded environments, 
such as among military recruits68. HAdV has also been responsible for many outbreaks within 
health care facilities, including neonatal wards69, ophtalmological clinics70 and pediatric long-
term care facilities71. There are several reports of HAdV transmission in HSCT wards, of 
which three (including our own) were type A31, one type F41 and one type A1249,72-75.  In a 
couple of the reports of HAdV A31 transmission continued during a long time, up to several 
years49,75.  
 
1.2.3 HAdV in the HSCT population 
1.2.3.1 Epidemiology 
The reported incidence of HAdV infection in HSCT patients varies depending on age of the 
patient, “transplant procedures”, the extent of testing and the material tested. Recent studies, 
from the last 10 years, have reported HAdV viremia in 10.5-26% of pediatric60,76-79 and 1.5-
12% of adult HSCT recipients76,80-83. HAdV disease has been diagnosed in 4-11% of 







There are no universally used definitions for manifestations of HAdV in the HSCT 
population. The following definitions were recommended by the 4th European Conference of 










Histological confirmation is not always possible, whereby proven disease may be less 
common. In this thesis, HAdV infection refers to the detection of HAdV in any sample, and 
disease refers to HAdV infection with corresponding signs and symptoms (with or without 
histological confirmation).  
1.2.3.3 Clinical picture 
Subclinical HAdV infections are common in patients having undergone HSCT58,83,84. 
Screening studies have shown that gastrointestinal symptoms are absent in 54-70% of 
patients with HAdV detected in feces, and 50-82% of patients with viremia remain 
asymptomatic, with or without pre-emptive treatment86. HAdV can cause a wide range of 
symptoms in HSCT patients:  mild disease including enteritis or upper respiratory symptoms, 
severe localized disease, such as colitis, hepatitis, hemorrhagic cystitis or pneumonia, or 
severe disseminated disease with multiple organ involvement and high mortality30. Young 
children have the highest risk of both HAdV infection and disease41.  However, in cases of 
dissiminated disease with multiple organ involvement, the mortality is high in both children 
and adults40,80,87. Other risk factors for HAdV infection and disease include in vivo or ex vivo 
T-cell depletion, grafts from unrelated or haploidentical donors, cord blood grafts, and 
- Systemic infection/viremia: Positive HAdV PCR, virus isolation, or antigen 
detection in peripheral blood. 
- Local infection: Positive HAdV PCR, virus isolation, or antigen detection in 
biopsy material or in body fluids other than peripheral blood. 
- Probable disease: HAdV infection plus corresponding symptoms and signs 
without histological confirmation. 
- Proven disease: HAdV infection plus corresponding symptoms related to the 




lymphopenia with CD3+ T-cell counts < 0.3 x 109/L 30. Absence of HAdV-specific T-cells is 
also linked to the development of HAdV disease88.  
1.2.4 Diagnosis and monitoring of HAdV 
Diagnosis of HAdV infection is today usually based on polymerase chain reaction (PCR) of 
peripheral blood or samples from feces, urine or respiratory secretions. Quantitative (q) PCR 
is a general routine for analyses of blood samples. Some centers also use qPCR for analyses 
of fecal samples, but this is not done at the Karolinska University Hospital.  
Rational for monitoring HAdV in peripheral blood: Rising levels of HAdV in peripheral 
blood is associated with HAdV related death and has been shown to precede clinical 
symptoms of HAdV by up to several weeks82,84,86. Due to the limited effect of HAdV therapy, 
especially in patients with disseminated disease, monitoring high risk patients for HAdV with 
qPCR in peripheral blood, and pre-emptive treatment is recommended in current 
guidelines30,86. However, there are no data showing beneficial effects on mortality with this 
strategy30.  
Rational for monitoring HAdV in feces: Several authors have reported of increasing HAdV 
levels in feces preceding viremia in pediatric HSCT patients24,47,59-61,79,89. In some reports a 
critical threshold of HAdV > 105-106 copies/gram feces preceded viremia by in median 6-11 
days59,60,89. Others have reported of a high amount of HAdV in feces being associated with 
viremia, although without a specific HAdV thresold in feces clearly preceding viremia47,61,79. 
In addition, Kosulin et al found that children with HAdV shedding in stool prior to HSCT had 
a significantly increased risk of viremia post HSCT24. These data have prompted 
recommendations of screening children for HAdV in feces prior to HSCT, and monitoring 
feces with qPCR during the first 100 days post HSCT30,40. In contrast, there are no data 
supporting monitoring adults for HAdV in fecal samples30. In a recent European survey, most 
HSCT centers monitored the patients for HAdV in blood (all patients 66%, and only high-risk 
patients 19% of centers). Monitoring of fecal samples was less common (26% of centers)90. 
 
1.2.5 HAdV antiviral treatment 
Cidofovir has in vitro virostatic effect against HAdV and has been reported to have some 
positive effect as pre-emptive treatment of HAdV infection and disease, although the efficacy 
can be limited when there is no concomitant immune reconstitution or in cases of multiorgan 
disease48,84,86,87,91. Renal toxicity is a common and serious side-effect40. The most frequently 
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used dose is 5mg/kg once a week, but for pre-emptive treatment a dosing regimen of 1 mg/kg 
three times per week is also used40,90,92.  
Brincidofovir is a lipid-conjugated derivative of cidofovir that has been associated with a 
significantly better viral response, even in patients with profound lymphopenia 93-95, but no 
prospective controlled study has been performed. Oral brincidofovir is not associated with 
nephrotoxicity, but gastrointestinal toxicity is common and therapy limiting96. The substance 
seems to be a promising treatment option for HAdV but is presently not available40. An 
intravenous formulation of brincidofovir is under investigation97. 
1.2.6 HAdV adoptive cellular therapy 
Adoptive transfer of donor derived HAdV-specific T cells have been studied with promising 
results98-101. The isolation and expansion of donor-derived HAdV-specific T-cells is time 
consuming and may not always be possible. HAdV-specific or multipathogen-specific T-cells 
from third party donors are being evaluated, which may provide a more universal and faster 
access to cell therapy102. 
 
1.2.7 Management of HAdV infection and disease 
In guidelines from the European Society of Blood and Marrow Transplantation  (EBMT) 
2018, screening of feces for HAdV twice prior to HSCT, and weekly monitoring of HAdV in 
both blood and feces with qPCR after HSCT, until recovery of CD3+ cells above 300/µL, is 
recommended for pediatric patients 30. For adults, there is no strong recommendation on 
HAdV monitoring30. At our center, monitoring of high-risk children for HAdV in blood was 
introduced in recent years. In addition, screening children for HAdV in stool, and screening 
all patients for respiratory viruses (including HAdV), prior to HSCT, has been implemented 
at the center lately. However, the method for quantification of HAdV in feces is currently not 
available at Karolinska University Hospital. There is no established threshold of HAdV DNA 
in blood or feces for initiating pre-emptive HAdV treatment. Tapering of immunosuppression 
should be done whenever possible, especially in patients with HAdV disease86. In a recent 
European survey, HAdV DNA levels of > 100 to > 10.000 copies/mL blood had been used as 
threshold for initiating pre-emptive treatment in the included HSCT centers90. Hiwarkar et al 
recommend pre-emptive treatment with cidofovir in the presence of viremia > 1000 
copies/mL and/or HAdV DNA in feces with rapidly rising levels above the suggested critical 




Norovirus is the leading cause of viral gastroenteritis worldwide. Norovirus gastroenteritis 
affects all age groups and is estimated to be responsible for 21 million cases and 500-800 
deaths yearly in the United States103,104. Typical symptoms are sudden onset of vomiting and 
diarrhea usually resolving within 2-3 days.  However, symptoms lasting for a median of 4-6 
days have been reported during hospital outbreaks and in immunocompetent young children, 
and in elderly people with co-morbidities norovirus has been associated with excess mortality 
105,106. The diagnosis of norovirus is mostly based on PCR of fecal or vomit sample107. There 
exists no specific treatment or vaccine against norovirus infection 108. 
 
Noroviruses are small non-enveloped RNA-viruses belonging to the family caliciviridae. The 
norovirus genus is divided into 6 genogroups (G), of which GI, GII and (to a very little 
extent) GIV cause infection humans109. The human genogroups are further divided into at 
least 34 genotypes110. Norovirus GII.4 is the dominating genotype globally since many years, 
and still is the most prevalent genotype in Sweden, although other genotypes have emerged 
as predominant in some other countries104,111. Globally circulating GII.4 strains are every few 
years replaced by new antigenically divergent GII.4 strains, which coincides with recurrent 
increased activity of norovirus outbreaks112. In immunocompetent individuals, norovirus 
GII.4 has been associated with a more severe clinical course than other genotypes, and more 
frequently causes vomiting113,114.  
 
1.3.1 Transmission 
Noroviruses are transmitted primarily by the fecal-oral route, but air-borne transmission (of 
aerosolized infectious vomit) also occurs115. Noroviruses are transmitted very efficiently due 
to several characteristics: the infectious dose is low (estimated to 18-1000 virus particles), 
viral shedding precedes the onset of symptoms and may peak after symptoms have resolved, 
and noroviruses are stable in the environment, persisting on surfaces, in food and in 
water114,116,117. Common hand disinfectants are not effective for norovirus, in parity with what 
is seen with HAdV107. Outbreaks are common, both in the community and, particularly, in 
health care facilities, and there are several reports of norovirus outbreaks in HSCT units118-121.  
Most nosocomial outbreaks of norovirus are caused by GII.4, possibly because norovirus 
GII.4 is associated with an increased risk for vomiting, in addition to GII.4 being the 
dominating strain in the communities114.  
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Norovirus RNA can be detected in stool for up to 100 days in immunocompetent people, and 
for even longer periods in immunocompromised individuals, after resolution of 
symptoms122,123. However, it is not known if detection of norovirus RNA a long time after 
symptoms have resolved represents infectious viruses with the potential of transmission. 
 
1.3.2 Secretor-status 
Host genetic factors play an important role for the susceptibility to norovirus infection. The 
ability of several norovirus strains to infect humans strongly depends on the presence of 
different histo-blood group antigens (HBGAs) on gut mucosal surfaces. At least 20% (21.5-
28%) of the Swedish population do not express certain HBGAs on their epithelial cells due to 
homozygous inactivating mutations in the α1,2-fucosyltransferase 2 (FUT2) gene124,125. 
These individuals are termed secretor-negative and are with few exceptions protected against 
the dominating genotype of norovirus (GII.4)110.  It is not known if secretor-status is 
associated with the susceptibility to norovirus infection also in immunocompromised 
individuals, or if secretor-status can influence the clinical course of norovirus infection in 
these patients.  
 
1.3.3 The immune response to norovirus 
There is very little knowledge of how the human immune system interacts with norovirus, 
both in terms of protective immunity and clearance of the infection. Humoral response may 
have an important role, since increased levels of antibodies blocking the binding between 
virus like particles (VPL, a surrogate for virus) and HBGA is associated with a lower risk of 
becoming ill from norovirus107 Further, in a case report of a patient with chronic norovirus 
infection, the infection resolved at the development of strain-specific HBGA-blocking 
antibodies126. Thus, B-cells might be important both for preventing and clearance of 
norovirus infection107. T-cells are also activated when exposed to norovirus, in line with what 
is seen in other viral infections, although their role in controlling norovirus has been less 
clarified127.  
 
1.3.4 Norovirus in the immunocompromised patient 
In immunocompromised patients, norovirus is increasingly acknowledged as a cause of 
chronic and/or severe gastroenteritis. This has been described in patients after solid organ 
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transplantation128-131, and in patients with hematological malignancy 120 and primary 
immunodeficiency disorders 132-134. There is limited knowledge of norovirus in the HSCT 
setting. Some authors have reported of norovirus infection causing chronic diarrhea and 
malnutrition, requiring TPN for several months up to a year, occasionally with lethal outcome 
135-137. In other reports the duration of symptoms was considerably shorter (median 7-12,5 
days), although the clinical picture was severe in some of the patients, requiring admission to 
the intensive care unit, and with several deaths that may have been complications of 
norovirus infection 120,138. Further, in two reported outbreaks of norovirus in HSCT units, 
there were no severe cases 118,119. There is little knowledge of risk factors associated with a 
severe or prolonged course of norovirus infection in patients undergoing HSCT. 
 
1.4 HEPATITIS E VIRUS 
There are four genotypes of HEV causing disease in humans. HEV genotype 1 (HEV1), 
and to a lesser extent HEV 2, are responsible for large waterborne outbreaks as well as 
sporadic cases of acute hepatitis in low-income countries 139. HEV 3 and HEV 4 are 
endemic in industrialized countries, causing zoonotic infections, with HEV3 being the 
predominant genotype, and HEV4 mainly found in high-income areas in Asia139. Recently 
an additional four HEV genotypes (HEV5-8) have been discovered in wild animals. 
Infection with these HEV genotypes have been described in a couple of case reports, 
although the clinical relevance for humans remains to be clarified140.  
The clinical picture varies depending on the HEV genotype. HEV1 and HEV2 cause acute 
icteric hepatitis in 5-30% of the cases, and fulminant hepatitis with high mortality can 
occasionally occur, especially in pregnant women for whom mortality can be as high as 15-
25%139.  HEV1 and HEV2 have not been associated with chronic infection. The diagnosis 
of HEV should be based on a combination of serology and HEV RNA, and for 
immunocompromised individuals only HEV RNA is recommended141. 
 
1.4.1 HEV3, epidemiology 
The prevalence of anti-HEV IgG in Europe varies greatly depending on the serological 
method used, geographical area and type of population. The seroprevalence increases with 
age and is higher among individuals exposed to swine and/or wild animals142. In Sweden the 
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prevalence of anti-HEV IgG is 9-16%143,144, whereas in France and Germany the reported 
seroprevalence is higher, up to 52% in southwest of France142.  
 
1.4.2 HEV3, transmission 
Transmission of HEV3 occurs through the fecal-oral route, mainly by ingestion of 
insufficiently cooked meat from infected animals145. The primary reservoir for HEV3 are 
pigs, but other domestic and wild animals, such as wild boar, deer, rabbits, cattle, sheep and 
horses, can also be infected. In addition, shell-fish and fruits or vegetables watered with 
contaminated water may transmit HEV140. There are also increasing data supporting 
transmission by blood products146, and a few cases of transmission from donors of stem cells 
or solid organs have been reported147,148. HEV ribonucleic acid (RNA) has been detected in 
0.01 % of Swedish blood donors 149. The prevalence of HEV RNA in blood donors varies 
between different European regions and has been up to 0.12–0.13% in certain regions of 
France and Germany150. Several European countries have implemented HEV RNA screening 
of blood products and donors of stem cells, but such screening is currently not performed in 
Sweden150. 
 
1.4.3 HEV3, Clinical picture 
HEV3 causes acute self-limiting hepatitis in healthy people, but the majority of HEV3 
infections are subclinical151. Individuals with pre-existing liver disease carry an increased risk 
for acute liver failure upon infection with HEV3140, and extrahepatic manifestations including 
thrombocytopenia, glomerulonephritis and neurological symptoms have been linked HEV 
infection139,152.  
 
1.4.4 HEV3 in immunocompromised patients and in the HSCT setting 
HEV3 can cause chronic infection and rapid advancement to liver cirrhosis in 
immunocompromised patients. This has mostly been described in SOT recipients153, but also 
in patients with HIV 154, rheumatological disorders155 and hematological malignancy 156. The 
reported frequency of patients tested positive for HEV RNA after HSCT has been 0% in two 
small cohorts157,158, and 0.4- 2.4% in larger cohorts with 111-328 patients39,159,160. Moreover, 
Willemse et al detected HEV RNA in 5/123 (4%) HSCT patients with elevated ALT161. In 
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HSCT patients infected with HEV, up to 63% may develop chronic infection, and the clinical 
course can be severe39,161. Carre et al have reported of a case of fatal fulminant HEV infection 
early after HSCT162, and in a retrospective European multicenter study, HEV contributed to 
liver related death in two patients163. In contrast in another multicenter study, no HEV related 
deaths were found among 25 HSCT patients with HEV infection164. 
 
1.4.5 HEV3, treatment 
The experience of treating HEV infections is limited, and mostly involves solid organ 
transplant recipients165. Reduction in immunosuppression can lead to clearance of HEV 
infection in approximately 30% of solid organ transplant patients with persistent 
infection166. Also in HSCT patients, chronic HEV infection has resolved during tapering of 
immunosuppressive drugs39,164. Ribavirin has been associated with clearance of HEV 
infection in several studies of solid organ transplant patients167-169.  Although data on 
treatment of HSCT patients with HEV is limited, case reports and series indicate that 























2.1 GENERAL AIMS 
To study the clinical importance of viral gastrointestinal infections in HSCT recipients, with 
focus on adenovirus, norovirus and hepatitis E.  
 
2.2 SPECIFIC AIMS  
 - To investigate transmission within a health care facility  
 - To determine the clinical picture and outcome  
 - To determine risk factors for severe and/or long-term infection 

















3 STUDY POPULATION 
The patients studied had all undergone HSCT 2005-2016 at CAST, Karolinska University 
Hospital Huddinge. The conditioning regimens, GVHD prophylaxis and supportive care 
procedures at the center were previously described170,171. Haploidentical transplants were 
performed using post-transplantation cyclophosphamide according to Luznik et al or Raiola 
et al172,173 and since 2013  alpha/beta T-cell depletion was used for some patients174. 
All patients were monitored for cytomegalovirus (CMV) on a weekly basis by a quantitative 
PCR and preemptive antiviral treatment was given as previously described. 175, Patients 
considered at high risk for PTLD (serological mismatch, unrelated or haplo-identical donor, 
cord blood stem cell source, aGVHD > II)  were also monitored weekly for Epstein–Barr 
virus (EBV) during the first 3 months after HSCT176. No general surveillance for HAdV was 
performed at our unit during the time of our studies, but testing was promptly done on 
suspicion of infection. In patients with gastrointestinal symptoms, microbiological testing of 
fecal samples was conducted, including PCR for noro-, sapo-, rota-, and adenovirus and 
detection of Clostridium difficile toxin, and in cases of protracted diarrhea also culture for 
Salmonella, Shigella, Campylobacter, and Yersinia and microscopy for parasites. Upper and 
lower endoscopies were performed at suspicion of gastrointestinal GVHD. 
Other methods, including microbiological and statistical analyses, are described in the section 
of results and discussion. 
 
The studies were approved by the Regional Ethical Board of Stockholm: 
Study I and II: DNR 2012/1506-31/4 
Study III: DNR 2017/1508-31/2 








4 RESULTS AND DISCUSSION 
4.1 PAPER I 
December 2011 to March 2012 there was an outbreak of HAdV A31 at our unit. We analyzed 
the outbreak, the possible routes of transmission, and the medical consequences.  
We studied all patients who were admitted at CAST during the outbreak (defined as the 
period from the first to the last verified case of HAdV A31 infection: December 12, 2011 to 
March 22, 2012). We also studied all patients diagnosed with HAdV infection from 
November 2011 to July 2012. Clinical data, and information of hospitalizations, visits to the 
out-patient clinic and the patient housing (mainly housing families with children), were 
retrieved from the medical records. We also collected information of hygiene and cleaning 
routines, and measures during the outbreak, respectively, from the staff at the ward.  
 
4.1.1 Detection and phylogenetic analyses of HAdV 
For detection of HAdV, a Taqman real-time PCR targeting the hexon gene was used, as 
previously described177,178. All HAdV strains identified during the outbreak, and the 
following 4 months, were typed. The HAdV type was determined as described by Allard et 
al179. Phylogenetic analysis of the hexon gene was conducted using primers and PCR 
programs according to Leruez-Ville et al73, with slight modifications presented in paper I.  
For phylogenetic analysis of the E3 gene, a 2-step PCR amplification of almost the entire 
HAdV E3 gene was performed using 8 sets of different pairs of primers designed from the 
known sequence of the HAdV A31 reference strain (AM749299.1). Further details are 
outlined in paper I. Sequencing and phylogenetic analyses were performed at the Department 
of Virology, Umeå Universtity, Umeå. 
 
4.1.2 Description of the outbreak 
Nine patients with HAdV A31 were identified. The outbreak is illustrated in Figure 2. Several 
measures were implemented:  
1. HAdV screening of all admitted patients on two occasions, and regular testing of those 
with symptoms,  
2. closing and disinfecting the common kitchen (day 38 of the outbreak),  
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3. transfer of all HAdV positive patients from the ward (day 46 of the outbreak).  
 
After these steps were taken, there were no new cases identified in the ward for a period of 
four weeks, although three patients in the out-patient clinic were found to be HAdV A31 
positive. These patients had all been previously admitted at the ward, at the same time as 
HAdV A31 positive patients. Transmission in the ward was thought to be over, and the 
kitchen reopened (on day 59 of the outbreak). However, two more cases of HAdV A31 were 
diagnosed on day 78 and 101 respectively (Figure 2) 
 
 
Figure. 2. Timeline of the human adenovirus (HAdV) outbreak. All samples were fecal samples except in Patient 
5 (plasma sample). Day refers to the day after the first identified HAdV A31 case. The bars indicate admission at 




4.1.3 Did transmission between the patients occur? 
Phylogenetic typing was conducted in all nine cases of HAdV A31 infection. Sequencing the 
hexon gene showed 100% homology between the patient strains, but also to reference strains 
of HAdV A31, whereby transmission among the patients could neither be concluded or ruled 
out. We therefore sequenced the more diverse E3 gene, revealing that the patient strains 
contained identical mutations not present in the reference strains, hence suggesting a common 
source of transmission. The hexon gene has a relatively low genetic variability49. In another 
reported HAdV outbreak among HSCT recipients, sequencing revealed similar results, with 
homology between the patient strains as well as the reference strains74.  
 
4.1.4 Possible routes of transmission 
All patients with HAdV A31 had been admitted to the ward. The two last cases (patients 8 
and 9) had no connection in time to the other identified HAdV positive patients in the ward, 
but no other possible interactions with HAdV infected patients (out-patient clinic or patient 
housing), were identified for those patients.  
The following factors may have contributed to transmission of HAdV: 
1. Although HAdV positive patients were isolated, transmission may have occurred indirectly 
through contaminated surfaces or fomites in the ward (HAdV contamination may have 
occurred before hygiene measures were implemented, and after reopening the kitchen).  
HAdV has been shown to remain infectious on surfaces for up to four weeks, and HAdV 
RNA can be detectable on surfaces for 3 months63,64. Monitoring of HAdV DNA in the 
environment after cleaning may be a way of preventing insufficient cleaning and 
environmental transmission of HAdV180,181. Houldcraft et al reported of a cluster of four 
patients with HAdV A31, who seemed to be part of a nosocomial transmission, which was 
supported by whole genome sequencing (WGS), although two of the patients had been 
admitted three years apart. Other HAdV A31 cases had been in the ward during this period of 
three years, and may have been part of the transmission, but in those cases WGS could not be 
performed49. Routine phylogenetic typing of HAdV strains in HSCT patients could be an 
important measure, enabling early discovery of HAdV transmission. 
2. Testing for HAdV at the end of the outbreak was less frequent, and unidentified cases, with 
mild or no symptoms, may have contributed to the continued transmission among patients in 
the ward. Asymptomatic HSCT patients can have high concentrations of HAdV in stool59. 
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3. It is also possible that staff members transmitted the virus between patients, although none 
of them reported any clinical symptoms during the outbreak. At the beginning of the 
outbreak, there was an excessive strain on the staff, due to several seriously ill patients in the 
ward, and hygiene routines may not always have been properly maintained. Short staffing has 
been reported to be a risk factor for transmission of pathogens between patients182,183. 
4. The ward used at the time was not optimal for infection control purposes, since some 
rooms did not have separate toilet and shower facilities. This has now been changed with the 
move to a new purpose-built transplant ward. 
 
4.1.5 Clinical consequences 
Transplantation was postponed due to HAdV, and later cancelled, in one patient. Five 
patients were treated with cidofovir because of high levels of viremia, but no patient 
developed severe disease. Seven patients had concomitant aGVHD grade II–IV, complicating 




An outbreak of HAdV among HSCT patients can be difficult to control. The clinical 
consequences were significant for some patients, although no patient developed severe HAdV 
disease. Contamination of the common facilities in the ward, and unidentified asymptomatic 









4.2 PAPER II AND III 
In paper II, 63 patients having undergone HSCT and who were diagnosed with norovirus 
infection 2006-2012 were studied retrospectively. The aims were to determine the clinical 
importance of norovirus and identify risk factors for long-term symptoms. The duration of 
norovirus symptoms was defined as the number of days of diarrhea and/or vomiting with the 
concomitant detection of norovirus. Gastrointestinal symptoms lasting > 30 days (with 
continued detectable norovirus) were defined as chronic symptoms of norovirus. Other 
possible causes of gastrointestinal symptoms such as mucositis, GVHD or other infections, 
were also registered. In paper III, we analyzed if either secretor-status or norovirus genotype 
influenced the clinical course of norovirus infection following HSCT. In total 89 HSCT 
patients diagnosed with norovirus infection 2006-2016 were included in paper III, of whom 
63 also had been included in paper II. Clinical data were retrieved from medical records.  
 
4.2.1 Microbiological analyses  
Detection of norovirus RNA in fecal and vomit samples (paper II and III) was performed 
with a few different methods, as described in paper III. In patients for whom fecal samples 
were available, sequencing and phylogenetic analysis of the norovirus strain was performed 
(paper III), as previously described 184-186.  In paper III, we also investigated the possibility of 
detecting norovirus RNA in stored blood samples (the first available sample after the 
diagnosis of the norovirus infection), for further genotyping, as previously has been reported 
132,187. We chose to first analyze samples from patients with known genotype (available fecal 
samples), as a pilot study, and expand to test all patients if we found positive results. For the 
detection of norovirus RNA in blood, a multiplex TaqMan real-time PCR was used, as 
previously reported, with slight modifications 184,188,189. The phylogenetic analyses and 
detection of norovirus in blood were performed at the Department of Clinical and 
Experimental Medicine, Linköping University, Linköping. The details of these methods are 
presented in the supplementary material of paper III.  
4.2.2 Secretor-status 
This analysis was also conducted at the Department of Clinical and Experimental Medicine, 
Linköping University. To determine the secretor-status of the HSCT recipients, we used 
samples collected at the time of HSCT, either stored extracted DNA, or whole blood from 
which DNA was extracted, as presented by Bucardo et al190. The extracted DNA was 
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analyzed for the FUT2 G428A (rs601338) nonsense single nucleotide polymorphism (SNP), 
using the TaqMan® SNP Genotyping Assay (Applied Biosystems, Carlsbad, CA, USA)190.  
 
4.2.3 Statistics 
The logistic regression method was used for analysing factors associated with chronic 
symptoms (>30 days). Factors with a p-value ≤0.20 in the univariate analysis were introduced 
into the backward elimination (study II) or stepwise selection (study III) multivariate 
analysis. For study II, Statistica software (StatSoft, Tulsa, Oklahoma, USA), and for paper 
III, R software (R Core Team, Vienna, Austria), were used. Time independent variables were 
analyzed separately from time dependent variables. 
In paper III, the Mann-Whitney test was used for assessing differences in symptom duration 
and viral load between norovirus GII.4 vs norovirus non-GII.4. 
 
4.2.4 Results and discussion 
The duration of symptoms in the 89 patients was in median 9 (1-681) days, and 18/89 
(20%) patients had chronic symptoms of norovirus (>30 days). SCID diagnosis, as the 
indication for HSCT, was associated with chronic symptoms of norovirus in paper II (OR 
30.3, CI 2.5-368, p<0.05), which was confirmed in paper III (OR 10.7, CI 1.8-62.1, 
p=0.01). The number of patients with SCID was 5/63 patients in paper II and 8/89 patients 
in paper III. Further, in paper III, we found that patients with chronic symptoms of 
norovirus had a significantly higher probability of concurrent gastrointestinal GVHD (OR 
11.0, CI 2.4-50.4, p<0.001). However, it was not always possible to determine if the 
symptoms were due to norovirus, GVHD or both. Nor can we conclude if GVHD increases 
the risk for chronic norovirus symptoms, or vice versa.  
Patients with SCID commonly have an impaired and delayed immune reconstitution after 
HSCT191,192, supporting that prolonged symptoms of norovirus are linked to poor immune 
status of the patient. We found no connection between chronic norovirus symptoms and ALC 
(study II) or lymphopenia < 0.2 X 109/L (study III), but detailed immunological 
characteristics of the patients are lacking. In a case series of HSCT children with chronic 
norovirus infection, reconstitution of CD3+ T-cells was linked to clearance of the 
infection136, and immunological control of several other viral infections is strongly associated 
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with the reconstitution of T-cells58,59,193. Studies focusing on the significance of different 
immunological factors for the control of norovirus in immunocompromised patients are 
needed.    
GVHD impairs the immune status of the patient, both directly due to the GVHD and, in 
addition, due to its treatment. The association between gastrointestinal GVHD and chronic 
norovirus symptoms found in study III may further indicate the importance of the immune-
status for the course of norovirus infection. Norovirus may, on the other hand, increase the 
risk for development of gastrointestinal GVHD. Montfrans et al found that shedding of 
gastrointestinal viruses prior to HSCT predicted development of intestinal GVHD194. 
Norovirus has also been linked to chronic GVHD, although as in our study, the cause and 
effect relationship was unclear137.  
In paper II and III, 47/89 (53%) patients had at least one other gastrointestinal condition 
(mucositis, gastrointestinal GVHD or other gastrointestinal infection) concurrently with the 
norovirus infection (for a part of or during the whole course of the infection), which may 
have contributed to the symptoms. As in our study of adenovirus, we found it difficult to 
determine if the gastrointestinal symptoms were primarily due to norovirus infection, or to 
gastrointestinal GVHD, or if both conditions were causing the symptoms.  
 
4.2.4.1 Transmission and indirect consequences 
We observed an accumulation of six patients with onset of symptoms > 48 hours after 
hospital admission (defined as nosocomial infections), occurring within a period of three 
weeks, which may have constituted an outbreak. Among the first 63 patients (paper II), we 
registered indirect consequences of the norovirus infection, and found that HSCT was 
postponed in one patient, and four patients were not accepted for endoscopy (for suspected 
GVHD) due to the norovirus infection. One of these patients was later terminally ill, 
because of relapse, and was not accepted for palliative homecare due to the infection.  
 
4.2.4.2 Secretor-status 
7/89 (8%) of the patients were secretor-negative, which is a significantly smaller proportion 
compared to the general population (p=0.004), indicating that secretor-negative genotype 
protects against norovirus infection even when the immune system is severely compromised. 
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We found no association between secretor-status and chronic symptoms of norovirus (>30 
days). However, due to the small number of secretor-negative patients, this result should be 
interpreted cautiously.  
4.2.4.3 Norovirus genotype 
Previous data suggest that norovirus GII.4 is associated with a more severe clinical picture 
compared to other genotypes in immunocompetent children113. The importance of norovirus 
genotype in relation to the clinical course has not been reported of in immunocompromised 
patients. Genotyping of norovirus was possible in 18 patients, demonstrating GII.4 in 12 of 
them. We compared the patients with norovirus GII.4 with those infected with other 
genotypes (in total ten patients, including four with GI, not genotyped), termed non GII.4. We 
found a possible difference in symptom duration between norovirus GII.4 and non GII.4. The 
symptoms lasted in median 36 (3-681) days in patients with norovirus GII.4, compared to 15 
(1-94) days in patients with norovirus non GII.4 (p=0.1). All the patients with norovirus GII.4 
were secretor-positive. 
These results may indicate that norovirus genotype influences the clinical course also if the 
patient is immunocompromised. However, as the number of patients with identified norovirus 
genotype was small, also these results should be interpreted cautiously. Stored fecal samples 
were lacking in most patients, and thereby there was no opportunity for norovirus 
genotyping. We investigated if norovirus could be detected in blood, primarily for the 
possibility of obtaining the norovirus genotype in additional patients, as have been shown in a 
few other studies132,187. Blood samples from the subgroup of 18 patients with a known 
genotype, were all negative for norovirus RNA, and we decided not to proceed with the 
remaining patients.  
4.2.5 Conclusions 
Norovirus is an important pathogen in the HSCT setting, causing chronic symptoms in 
approximately 20% of the patients. Our results indicate that secretor-negative genotype 
protects against norovirus infection, even in immunocompromised patients. Susceptibility to 
norovirus may thereby depend on genetic rather than immunological factors. When infected 
however, HSCT patients with SCID are at risk for chronic symptoms of norovirus, which 
may be due to the slow immune recovery in many of these patients.  Gastrointestinal GVHD 
was also linked to chronic norovirus symptoms, but it was not possible in all patients to 
determine if either, or both, conditions were causing the symptoms. 
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4.3 PAPER IV 
HEV can cause chronic hepatitis and liver cirrhosis in immunocompromised patients. The 
aim of study IV was to determine the prevalence and the clinical importance of HEV 
infection in a Swedish cohort of HSCT recipients. Our hypothesis was that HEV infection 
could be responsible for abnormal liver function tests in a subset of HSCT patients and 
thereby possibly be misinterpreted as chronic GVHD of the liver. 
We studied 236 patients who had undergone HSCT during the period 2008–2015. These were 
patients who had been included in a previous prospective study (with blood samples drawn at 
several time points after HSCT), and for whom blood samples collected at six months after 
HSCT were available. We chose the timepoint six months for the screening samples based on 
several considerations. First, we had readily access to a collection of samples from this point 
in time. Secondly, available data suggested that patients with HEV infection early after HSCT 
had a high risk of long-term HEV viremia, and HEV detection at six months could therefore 
be likely, even if the infection had been contracted earlier39. Third, this was a time when 
chronic GVHD was common. 
The blood samples were analyzed for HEV RNA, anti-HEV IgG, and IgM antibodies. In 
patients who were positive for HEV RNA and/or had anti-HEV antibodies at six months, we 
analyzed HEV RNA and HEV serology in samples collected from the patients, and their 
donors, at the time of HSCT. In the HEV RNA positive patients, a series of samples were 
analyzed to determine the duration of viremia. If samples were not available (from the sample 
collection of the previous prospective study), the biobank at the laboratories of Clinical 
Microbiology and Immunology were queried. Serum, plasma or whole blood was used for 
HEV RNA detection, and serum or plasma for serology. The HEV genotype was determined 
by phylogenetic analysis. Cases with verified HEV infection (positive HEV RNA) were 
compared to matched controls. Clinical data was retrieved from the medical records, 
including the level of alanine amino transferase (ALT) and bilirubin at three and six months, 
the occurrence of active GVHD at three and six months, and the level of systemic 
corticosteroid treatment at 6 months after HSCT.  
 
4.3.1 Microbiological analyses 
All microbiological analyses were performed at the Department of Clinical Microbiology, 
Sahlgrenska University Hospital, Gothenburg. Anti-HEV IgG and IgM were analyzed using 
the HEV IgG/IgM test (Diapro, Milan, Italy) in line with the manufacturer’s instructions, but 
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with modification of the cutoff levels, according to Norder et al144. For detection of HEV RNA, 
reverse transcription real-time PCR was conducted, as outlined by Roth et al195. Quantification 
of HEV RNA was performed using digital droplet PCR (ddPCR). The details of this method 
are presented in the supplementary material of paper IV. Briefly, the isolated RNA was 
subjected to reverse transcription to generate cDNA. A ddPCR reaction was set up using 
cDNA. An emulsion PCR reaction was performed, and the resulting droplets were counted. 
This method for quantification of HEV RNA was chosen since it required a small amount of 
blood, and the volume we could obtain from the initial samples collected at 6 months (50µl) 
was too small for conventional qPCR. Sequencing and phylogenetic analysis of the HEV 
strains were performed as previously described by Roth et al.195. For patients with chronic 
infection (> 6 months), the HEV strains in samples drawn at two different time points were 
sequenced.  
4.3.2 Statistics  
For patients with HEV infection (positive HEV RNA), two controls were randomly selected, 
matched for age, conditioning regimen, type of stem cell donor, and diagnosis (controls 
match 1). Two additional controls, for the same patients, were selected by matching for age, 
sex, and transplantation year (controls match 2), to evaluate if possible associations were 
linked to factors in match 1 (or match 2), or to the HEV infection. The controls were picked 
from the population who were negative for both HEV RNA and anti-HEV antibodies. Odds 
ratios (OR) for abnormal liver function tests and GVHD were computed for verified cases 
versus controls match 1 and match 2.  
 
4.3.3 Results and discussion 
HEV RNA was detected in 8/236 (3.4%) patients 6 months after HSCT, which is in line with 
a number of previous reports39,160,161. Three of the HEV RNA-positive patients (patient 1, 2 
and 3) had persistent viremia (repeatedly positive HEV RNA) and are presented in Figure 3. 
Two of these patients had chronic HEV infection (>6 months) and were infected already at 
the time of HSCT. In the remaining five patients, a low level of HEV RNA was detected at 
only one occasion (six months after HSCT). In two of these patients, the duration of infection 
could not be determined (due to death shortly after HEV RNA detection, and lack of samples, 
respectively), but in the other three patients, a short duration of viremia was demonstrated. In 
contrast, others have reported of a higher proportion of long-term viremia in HSCT patients 
with HEV infection39,161. In four patients with low-level HEV RNA, the samples were 
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positive in both RT-PCR and ddPCR, and in one of these strains sequencing could be 
performed.   
4.3.3.1 The clinical picture 
One patient developed lethal acute liver and multiple organ failure 8 months after HSCT, 
where HEV infection may have contributed to the severe course (patient 2, Figure 3). 
Another patient died, shortly after HEV was detected, but the death was not related to HEV. 
The remaining six patients with HEV RNA had cleared the infection at 7–24 (median 8.5) 
months after HSCT. HEV infection was associated with elevated alanine aminotransferase 
(ALT) > 3 upper limit of normal (ULN) at 6 months after HSCT (OR 15, 1.3–174, p = 0.03). 
In HSCT patients with liver abnormalities, microbiological testing for hepatic infections 
including HEV should be performed, and in unclear cases liver biopsy should be considered. 
Notably, we found normal ALT during several months, concurrent with high levels of HEV 
viremia, in the patient who later developed acute liver failure (patient 2, Figure 3), indicating 
that the diagnosis of HEV infection can be challenging. It is however difficult to draw 
conclusions from current data, whether screening (or monitoring) of HSCT patients for HEV 
infection should be recommended. 
Active GVHD of the liver was present in 3/8 patients at the time of HEV infection, but there 







Figure 3. The course of HEV infection in the three patients with persistent viremia (patients 1, 2 and 3). The 
levels of HEV RNA, measured by digital droplet PCR (ddPCR), are displayed. ALT, alanine aminotransferase; HEV, 
hepatitis E virus; HSCT, hematopoietic stem cell transplantation. The ALT upper limit of normal is 0.76 for females 
(patient 2) and 1.20 for males (patient 1 and 3).  Patient 1 was infected with HEV one month before HSCT. At the time of 
transplantation, HEV RNA was detected with real time PCR (RT-PCR), but the levels could not be assessed with ddPCR 
(indicated by *). Acute GVHD of the gut evolved, but HEV cleared during tapering of the corticosteroids. Patient 2 was 
infected with HEV at the time of HSCT. Mild chronic GVHD of the gut was diagnosed at six months, and infectious 
endocarditis at seven months after HSCT. Acute lethal liver and multiorgan failure developed eight months after HSCT. 
Patient 3 became positive for HEV RNA 1-3 months after HSCT. He had at that time acute GVHD of the gut, followed by 
mild chronic GVHD of the liver, but cleared HEV during reduction of the corticosteroids.  
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4.3.3.2 The source of HEV infection 
Sequencing of the HEV strains was possible in four patients, revealing HEV3f in three 
patients and HEV3c/i in one patient. HEV3f and HEV3c/i have both previously been detected 
in Swedish blood donors196, and HEV3f has been identified in Swedish pigs and wild boar197, 
whereas HEV3c/i has been found in pigs and wild boar in other European countries198.  
 
Both blood products and donations of stem cells have been reported to transmit HEV146,147. In 
our study, transfusion of erythrocytes and/or thrombocytes had been given to 4/8 patients 
within three months prior to the first detection of HEV RNA. No blood product was available 
for analysis. Thus, infected blood components may have been a source of HEV infection. All 
donors of the patients with HEV infection were negative for HEV RNA. Although several 
European countries have implemented HEV screening of blood components and donors of 
stem cells, this has not been introduced in Sweden150. The reported prevalence of HEV RNA 
in Swedish blood donors has been 0.01%, which is 10-fold lower than in some other 
countries, where the prevalence has been up to 0.13%149,150. However, the prevalence may 
change over time, and a continuous surveillance of the local prevalence is important199.  
 
Apart from possible transmission of HEV from blood products, the patients may contract 
HEV by contaminated food products139. At our center, the patients have diet 
recommendations, leaving out poorly cooked meat and shell fish, but contaminated food may 
still have been a possible source of HEV infection.   
 
4.3.3.3 The relevance of anti-HEV antibodies for diagnosis of HEV infection following 
HSCT 
The prevalence of anti-HEV antibodies at 6 months after HSCT was 4.7% in our cohort, 
which is low compared to the HEV seroprevalence of 16% found in Swedish blood donors144. 
Interpretation of anti-HEV serology should be done cautiously in patients having undergone 
HSCT, especially early after the transplantation, or when the immune reconstitution is 
delayed. Antibodies may be passively transferred to the HSCT patient, through blood 
components or intravenous immunoglobulin. In addition, antibodies and antibody-producing 
cells may be transferred from the stem cell donor200. Conversely, the antibody response to 
HEV may be weak or absent in these patients, due to their compromised immune status. 
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During the first 3-12 months after HSCT, or longer, the antibody production is deficient, as 
the recipient’s plasma cells are replaced with those of the donor, which was reported of for 
several other viruses200. Koenecke et al reported a seroprevalence of 6% in patients with 
unexplained ALT after HSCT, which is similar to our result158. In our study one patient with 
chronic HEV infection only developed transient anti-HEV IgM, but no anti-HEV IgG 
antibodies (patient 2, Figure 3), and among the patients with short term viremia, none 
developed anti-HEV antibodies. These results underline that diagnosis of HEV infection in 
HSCT patients should be done with HEV RNA detection39.  
4.3.4 Conclusions 
 HEV infection is an important differential diagnosis in patients with elevated liver enzymes 
after HSCT. Since the clinical course can be severe, and liver function tests may be only 




• An outbreak of HAdV among HSCT patients is a serious event that can be difficult to 
control. High strain on the staff during the early part of the outbreak, possible 
contamination of the facilities of the ward, and unidentified cases with sparse 
symptoms, may have contributed to the prolonged outbreak of HAdV A31 at our 
center.  
• Norovirus causes chronic symptoms (> 30 days) in 20% of HSCT patients.  
• SCID as indication for HSCT, and gastrointestinal GVHD, are associated with 
chronic symptoms in patients having norovirus infection.  
• Secretor-negative genotype may protect HSCT recipients against norovirus infection. 
• Difficulties to discriminate symptoms of HAdV, or norovirus, from symptoms of 
gastrointestinal GVHD, are a significant clinical challenge. 
• HEV infection is a potentially severe differential diagnosis in patients with elevated 








6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
6.1 GASTROINTESTINAL INFECTION VERSUS GVHD 
Gastrointestinal symptoms and liver abnormalities are common early after HSCT. Diarrhea 
and vomiting are usually caused by toxicity of chemotherapy or other drugs, GVHD, tube 
feeding, or gastrointestinal infections. Similarly, elevated liver function tests can be caused 
by drug toxicity, GVHD, or infections. In addition, liver affection can be a sign of veno-
occlusive disease, parenteral nutrition, or hemochromatosis. In the studies of HAdV and 
norovirus in the present thesis, we observed difficulties to determine if the patients’ 
symptoms were primarily due to the gastrointestinal infection, or due to gastrointestinal 
GVHD, when the histopathological diagnosis was inconclusive, or biopsy was not obtained. 
An additional complexity is that both GVHD and viral infection frequently occur 
concurrently, as is common for CMV gastrointestinal disease201,202.  
There may be several situations complicating the interpretation of gastrointestinal disease and 
concurrently detected norovirus RNA or HAdV DNA: 
- Previous shedding of norovirus RNA/HAdV DNA can be identified at the emergence of 
gastrointestinal symptoms from other causes, such as drug toxicity, GVHD or CMV colitis, 
and the symptoms may then be misinterpreted as norovirus/HAdV gastroenteritis.  
- Patients with shedding of norovirus/HAdV after resolution of symptoms may suffer from 
recurrence of gastrointestinal symptoms if they receive treatment that compromises the 
immune system. We observed a patient with shedding of norovirus, who experienced severe 
recurrence of gastrointestinal symptoms shortly after HSCT (and persisting after 
engraftment). 
- Norovirus/HAdV infection can be misinterpreted as GVHD, with immunosuppressive 
treatment aggravating the infection, which may in turn induce gastrointestinal GVHD, due to 
tissue damage194. In the case of HAdV, increased immunosuppression puts the patient at risk 
for invasive infection. 
- Gastrointestinal infection and GVHD may both cause the disease, where increasing as well 
as decreasing the immunosuppression may aggravate the symptoms, but for different reasons. 
- A new gastrointestinal infection with another pathogen might develop so that symptoms are 
not related to the previously documented one. 
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For patients with HAdV, this differential diagnostic problem is especially serious, since 
HAdV can progress to lethal disseminated disease, and invasive infection (viremia) should 
evoke reduction or withdrawal of the immunosuppressive treatment.  GVHD, on the other 
hand, also carries the potential to progress to lethal disease and requires increased 
immunosuppression. This potential problem has to our knowledge not been much reported of 
previously for HAdV.  
Norovirus is not associated with the threat of dissemination and lethal disease in HSCT 
patients, as for HAdV, although there are some reports of deaths where norovirus may have 
contributed120. However, the consequence of norovirus infection can still be serious. A child 
in our study had chronic severe diarrhea, with partial response to heavy immunosuppression, 
but the symptoms never resolved, and the patient eventually died of opportunistic infections 
almost two years after the diagnosis of norovirus infection. It is impossible to know to what 
extent norovirus may have caused an exacerbation of GVHD, or if norovirus was, to some 
degree, misinterpreted as GVHD. For some additional patients in our study, the problems 
separating norovirus symptoms from GVHD were less severe, but complicated the treatment 
of the patients significantly, as previously described by others120,135.   
 
Endoscopies with histopathological diagnosis is golden standard for the diagnosis of 
gastrointestinal GVHD. Histopathology is also required to confirm proven HAdV disease86. 
However, the histological picture is not always conclusive with respect to GVHD, and the 
histological diagnosis of HAdV may be difficult. 
Little is known of the histopathological picture during norovirus infection, and biopsy is not 
routine for diagnosis of norovirus gastroenteritis. Several authors have reported of villus 
blunting and epithelial infiltration of CD8+ T-lymphocytes in duodenal biopsies from 
immunocompromised patients with norovirus infection132,134,203, including three HSCT 
patients120. Although the picture is not specific for norovirus infection133, duodenal biopsy 
may be an important complement to colon biopsy to clarify whether GVHD or norovirus 
infection seems to be the dominating condition, since norovirus is a pathogen of the small 
intestine and GVHD might also develop in the upper gastrointestinal tract. In a recent report 
norovirus antigen and RNA were detected in small bowel biopsies from an 
immunocompromised patient, using immune histochemistry and in-situ hybridization, 
respectively204. Prospective studies investigating duodenal biopsies in HSCT patients, with 
and without norovirus infection, and evaluating norovirus antigen and/or RNA detection in 
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tissue, could provide important knowledge and a diagnostic tool in the treatment these 
patients.  
As for HAdV and norovirus, HEV infection may be mistaken for GVHD, which can lead to 
chronic HEV infection and rapid development of liver cirrhosis, due to the 
immunosuppressive treatment39,161. HEV infection may also coincide with GVHD of the 
liver, as was shown in our study, and possibly can activate or maintain GVHD of the liver161. 
There are, however, many different causes of elevated liver function tests, so careful 
assessment of possible differential diagnoses is important. HEV infection can be treated with 
ribavirin, which is generally well tolerated, and seems to be effective, although data is still 
sparse in the HSCT setting161,163,164. Thus, the dominating issue when it comes to HEV in 
HSCT patients, is to identify the infection. 
 
6.2 INDIRECT EFFECTS OF TRANSMISSIBLE VIRAL GASTROINTESTINAL 
INFECTIONS 
Norovirus and HAdV are easily transmitted and outbreaks especially of norovirus can occur 
in health care facilities. These may require closing of wards and postponed therapy for both 
infected and non-infected patients. We have investigated an outbreak of HAdV, and in the 
studies of norovirus, we recognized a possible outbreak involving six patients. Indirect 
clinical consequences of transmissible gastrointestinal viral infections are poorly 
understood. In the studies of this thesis we observed that indirect effects of HAdV and 
norovirus may be severe. During the outbreak of HAdV, transplantation was postponed in 
one patient, since he contracted HAdV after arrival at the ward. After this event, the parents 
did not want to proceed with the HSCT. Postponing transplantation can constitute a high 
risk for individual patients, such as relapse or progress of malignancy. Conversely, HSCT 
during HAdV enteritis carries a high risk for early invasive HAdV infection24. We also 
found potentially serious indirect consequences for some patients with norovirus infection, 
such as postponed HSCT and problems to get endoscopy performed. This last observation 
underlines that it can be a challenge preventing transmission of norovirus without 




6.3 INVESTIGATING INFECTIVITY 
Immunocompromised patients can shed norovirus RNA for a prolonged time, but it is not 
known if the detected RNA represents infectious viral particles123. The recent development of 
a cell culture system, so called enteroids, containing multiple intestinal epithelial cell types, 
has provided the possibility of culturing norovirus205. Chan et al inoculated norovirus RNA 
positive fecal samples from immunocompetent individuals in enteroid cultures, showing that 
norovirus was cultured only when the viral load was high (Ct-value < 30), suggesting the 
presence of infectious norovirus206. I am involved in a planned study of norovirus infectivity 
in immunocompromised patients, in collaboration with professor Lennart Svensson at the 
University of Linköping and Karolinska Institutet. We will prospectively include solid organ 
transplant and HSCT recipients with norovirus infection. Fecal samples collected serially will 
be inoculated in enteroids. The number of infected cells will be compared to the Ct-value 
obtained in the PCR. The study can provide information of the infectivity of norovirus, 
possibly related to the Ct-value, during the course of the infection in immunocompromised 
patients.  
6.4 UNDERSTANDING NOROVIRUS IN THE HSCT POPULATION 
Norovirus causes chronic symptoms in a subset of HSCT patients. In our study, SCID and 
concurrent gastrointestinal GVHD were associated with chronic norovirus symptoms, 
possibly due to impaired immune reconstitution in patients with these diagnoses. Prospective 
studies, investigating immunological components and norovirus genotype, in relation to the 
clinical symptoms, can confer important knowledge of factors linked to a chronic course of 
norovirus infection. To better evaluate the importance of secretor-status in this setting, 
prospective studies of secretor-status in HSCT patients, with and without norovirus infection, 
are warranted. The HSCT population can further be an interesting model for studies of the 
immunological control of norovirus.  
 
6.5 TREATMENT POSSIBILITIES 
The treatment options for HAdV are poor, and for norovirus treatment is lacking. Existing 
data on brincidofovir for HAdV seem promising, but brincidofovir is currently not available. 
Prospective controlled studies of new potentially active antiviral drugs against HAdV should 
be a high priority. Adoptive cell therapy for HAdV may prove to be an effective alternative, 
or can be a complement, and the development of this therapy is equally important. 
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For norovirus, the recent development of a cell culture system implies the opportunity to 
investigate antivirals. Several substances have been proposed as possible candidates, 
including ribavirin and nitazoxanide207. Therapeutic possibilities for norovirus could reduce 
the morbidity for HSCT patients, and other immunocompromised patients, with chronic 
norovirus infection.  
 
6.6 SCREENING STRATEGIES 
We found that elevated ALT six months after HSCT was associated with HEV infection. 
However, one of the patients in our study had normal liver function tests for a prolonged 
time, despite high level HEV viremia, illustrating that it may be difficult to identify some 
patients with HEV infection, solely on clinical suspicion. Versluis et al performed a cross-
sectional study of the point prevalence of HEV infection after HSCT. In addition, HEV 
analysis was conducted at time-points of elevated ALT (> 2.5 ULN). HEV RNA was 
detected in 8/328 (2.4%) patients, of which seven were identified in the cross-sectional 
analysis, and only one by screening the episodes of elevated ALT39. This raises the question 
of whether HEV screening or monitoring should be implemented. HEV infection is 
infrequent in the HSCT setting, and most patients in our study cleared the infection 
spontaneously, but the course of the infection may also be severe. It is therefore important to 
clarify risk factors for chronic infection, and moreover, to assess the prevalence of HEV in 
HSCT populations over time. Such insights can contribute to strategies for identifying 
patients with HEV: screening all patients depending on the local prevalence, screening 
identified high risk patients, monitoring all patients during a period of risk, or monitoring 
identified high risk patients? To gain this knowledge, larger prospective studies are 
warranted. Studies in areas with a high HEV prevalence may have a better chance of bringing 
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